<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00181220</url>
  </required_header>
  <id_info>
    <org_study_id>Valproic Acid NPC</org_study_id>
    <nct_id>NCT00181220</nct_id>
  </id_info>
  <brief_title>Valproic Acid in the Induction of EBV Lytic Cycle Antigen Expression in Nasopharyngeal Carcinoma</brief_title>
  <official_title>Valproic Acid in the Induction of EBV Lytic Cycle Antigen Expression in Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National University Hospital of Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <brief_summary>
    <textblock>
      The proposed study will test the safety and efficacy of sodium valproate in the induction of&#xD;
      Epstein-Barr virus (EBV) lytic cycle antigen expression in tumor tissue of patients&#xD;
      undergoing primary therapy for nasopharyngeal carcinoma. Up to 20 patients will be given&#xD;
      valproic acid for 2 weeks. The primary surrogate endpoint for efficacy will be expression of&#xD;
      EBV lytic antigens by immunohistochemistry in tumor tissue. Biopsies of primary tumor will be&#xD;
      taken after 2 weeks with achievement of a therapeutic concentration of valproate. Expression&#xD;
      of immunodominant EBV latency antigens in tumor tissue, EBV viral load by real time PCR, and&#xD;
      valproate levels will be measured. Adverse events associated with valproate in NPC patients&#xD;
      will be described.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    PI left JHU and is not able to be reached for updates&#xD;
  </why_stopped>
  <start_date>April 2004</start_date>
  <completion_date>September 2006</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>expression of EBV lytic cycle antigens in NPC tumor tissue.</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valproic acid</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All subjects must fulfill the following criteria to be eligible for study admission:&#xD;
&#xD;
          -  Subjects are of age 18 years and above&#xD;
&#xD;
          -  Biopsy proven nasopharyngeal carcinoma - WHO type 3&#xD;
&#xD;
          -  Must have tumor which is accessible to biopsy&#xD;
&#xD;
          -  For patients with disease localized to the PNS, the lesion must be visualized by&#xD;
             endoscopy&#xD;
&#xD;
          -  Subjects with metastatic disease with disease accessible to biopsy in the PNS if they&#xD;
             are deemed by their treating physicians not to require treatment for at least two&#xD;
             weeks.&#xD;
&#xD;
          -  An ECOG performance status of 0-2&#xD;
&#xD;
          -  For sexually active women of child-bearing potential, negative pregnancy test within&#xD;
             14 days of enrolling on trial&#xD;
&#xD;
          -  Must be able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  For patients with localized NPC, PNS lesions that cannot be visualized by endoscopy&#xD;
&#xD;
          -  Patients with disease inaccessible to biopsy&#xD;
&#xD;
          -  History of anaphylaxis after exposure to valproic acid&#xD;
&#xD;
          -  Hepatic dysfunction as defined by total bilirubin 1.0x upper limit of normal. AST&#xD;
             (SGOT) and ALT (SGPT) 3x upper limit of normal&#xD;
&#xD;
          -  Hemoglobin 8g/dl, Absolute neutrophil count 1500 cells/mm, and Platelet count 100,000&#xD;
             /mm&#xD;
&#xD;
          -  Creatinine 3x upper limit of normal&#xD;
&#xD;
          -  PT/PTT blood test result not within normal range&#xD;
&#xD;
          -  Patients who require treatment with an anticonvulsant besides valproic acid during the&#xD;
             course of valproate prescribed by the protocol&#xD;
&#xD;
          -  ECOG Performance status 3-4&#xD;
&#xD;
          -  Patients who are pregnant or breast feeding (Sexually active women of childbearing&#xD;
             potential must use contraception during course of therapy and within 4 weeks of&#xD;
             completion of trial)&#xD;
&#xD;
          -  Participation in another clinical trial involving therapeutic intervention within 4&#xD;
             weeks of enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen-son Hsieh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkin Singapore International Medical Center</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

